iSTOC has developed a disruptive mobile solution IDA (immediate diagnostics and analytics). The globally scalable end-to end solution has proven to be a powerful product and service, offering significant and innovative new business opportunities for iSTOC business partners and customers.
iSTOC IDA Platform captures and digitalizes lateral flow tests (LFT), including all major infectious diseases as well as blood typing, female and reproductive health and drugs of abuse.
You only need a mobile phone with a camera.
Our Web applications ensure real-time medical guidance back to the person using the mobile app.
Full integration to organizational and national databases.
Enables real time disease surveillance, epidemic alerts, management and communication.
iSTOC’s innovative approach to exploit mobile technology will disrupt the medical diagnostics market by changing the way how both healthcare professionals and consumers use their phones for better health.
iSTOC is growing globally, and the solution is used worldwide. Here are some quotes from our customers and partners.
As a Company Lifemed is committed to save lives, and our involvement to iSTOC IDA is one step further in the demonstration of our involvement against the Covid-19 pandemic.
Through our partnership with iSTOC, we have developed a comprehensive, turn-key COVID-19 testing solution. The innovative IDA platform, real-time analytics and interactive mapping provide vital testing data to our clients in both the public and private sectors. Together with iSTOC, we are deploying practical, scalable, testing programs to slow the spread of COVID-19, reopen the workplace and revitalize the US economy.
We are grateful to contribute to development of this Digital Point of Care, merging our monitoring health solution to IDA cloud and linking the information to patient Vitals and EMR.
Our partnership with iSTOC is a key for making our newly developed devices widely available for the benefit of our customers. With a license to the iSTOC IDA platform, CEMAG can focus on Covid-19 epidemiology and better individual access to related diagnostics.